Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

Barkauskas et al., Annals of Internal Medicine, doi:10.7326/M22-1503, ACTIV-3/TICO, NCT04501978

Aug 2022

Source PDF All Studies Meta AnalysisMeta

RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg.

Important missing comments or errors? Let us know.

risk of death, 17.0% lower, HR 0.83, p = 0.46, treatment 30 of 247 (12.1%), control 35 of 238 (14.7%), NNT 39, Kaplan–Meier, day 90.

risk of no recovery, 5.7% lower, HR 0.94, p = 0.55, treatment 44 of 247 (17.8%), control 48 of 238 (20.2%), NNT 42, adjusted per study, inverted to make HR<1 favor treatment.

risk of no recovery, 7.5% higher, HR 1.08, p = 0.68, treatment 247, control 238, adjusted per study, inverted to make HR<1 favor treatment, pulmonary ordinal outcome, day 5.

risk of no hospital discharge, 6.5% lower, HR 0.93, p = 0.46, treatment 28 of 247 (11.3%), control 34 of 238 (14.3%), adjusted per study, inverted to make HR<1 favor treatment.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Barkauskas et al., 9 Aug 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 80 authors, study period 11 June, 2021 - 15 November, 2021, average treatment delay 8.0 days, trial NCT04501978 (history) (ACTIV-3/TICO).

This Paper Ensovibep All

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

Christina Barkauskas, Eleftherios Mylonakis, Garyfallia Poulakou, Barnaby E Young, David M Vock, Lianne Siegel, Nicole Engen, Greg Grandits, Nilima R Mosaly, Andrew M Vekstein, Ralph Rogers, Fadi Shehadeh, Matthew Kaczynski, Evangelia K Mylona, Konstantinos N Syrigos, Vasiliki Rapti, David C Lye, Diong Shiau Hui, Lindsay Leither, Kirk U Knowlton, Mamta K Jain, Rubria Marines-Price, Alice Osuji, J Scott Overcash, Ioannis Kalomenidis, Zafeiria Barmparessou, Michael Waters, Karla Zepeda, Peter Chen, Sam Torbati, Francis Kiweewa, Nicholus Sebudde, Eyad Almasri, Alyssa Hughes, Sanjay R Bhagani, Alison Rodger, Uriel Sandkovsky, Robert L Gottlieb, Eriobu Nnakelu, Barbara Trautner, Vidya Menon, Joseph Lutaakome, Michael Matthay, Philip Robinson, Konstantinos Protopapas, Nikolaos Koulouris, Ivan Kimuli, Amiran Baduashvili, Dominique L Braun, Huldrych F Günthard, Srikanth Ramachandruni, Robert Kidega, Kami Kim, Timothy J Hatlen, Andrew N Phillips, Daniel D Murray, Tomas O Jensen, Maria L Padilla, Evan X Accardi, Katy Shaw-Saliba, Robin L Dewar, Marc Teitelbaum, Ven Natarajan, Sylvain Laverdure, Helene C Highbarger, M Tauseef Rehman, Susan Vogel, David Vallée, Page Crew, Negin Atri, Adam J Schechner, Sarah Pett, Fleur Hudson, Jonathan Badrock, Giota Touloumi, Samuel M Brown, Wesley H Self, Crystal M North, Adit A Ginde, Christina C Chang, Anthony Kelleher, Stephanie Nagy-Agren, Shikha Vasudeva, David Looney, Hien H Nguyen, Adriana Sánchez, Amy C Weintrob, Birgit Grund, Shweta Sharma, Cavan S Reilly, Roger Paredes, Agnieszka Bednarska, Norman P Gerry, Abdel G Babiker, Victoria J Davey, Annetine C Gelijns, Elizabeth S Higgs, Virginia Kan, Gail Matthews, B Taylor Thompson, Philippe Legenne, Richa Chandra, H Clifford Lane, James D Neaton, Jens D Lundgren, Christina Barkauskas, Eleftherios Mylonakis, Garyfallia Poulakou, Barnaby E Young, David M Vock, Lianne Siegel, Nicole Engen, Greg Grandits, Nilima R Mosaly, Andrew M Vekstein, Ralph Rogers, Fadi Shehadeh, Matthew Kaczynski, Evangelia K Mylona, Konstantinos N Syrigos, Vasiliki Rapti, David C Lye, Diong Shiau Hui, Lindsay Leither, Kirk U Knowlton, Mamta K Jain, Rubria Marines-Price, Alice Osuji, J Scott Overcash, Ioannis Kalomenidis, Zafeiria Barmparessou, Michael Waters, Karla Zepeda, Peter Chen, Sam Torbati, Francis Kiweewa, Nicholus Sebudde, Eyad Almasri, Alyssa Hughes, Sanjay R Bhagani, Alison Rodger, Uriel Sandkovsky, Robert L Gottlieb, Eriobu Nnakelu, Barbara Trautner, Vidya Menon, Joseph Lutaakome, Michael Matthay, Philip Robinson, Konstantinos Protopapas, Nikolaos Koulouris, Ivan Kimuli, Amiran Baduashvili, Dominique L Braun, Huldrych F Günthard, Srikanth Ramachandruni, Robert Kidega, Kami Kim, Timothy J Hatlen, Andrew N Phillips, Daniel D Murray, Tomas O Jensen, Maria L Padilla, Evan X Accardi, Katy Shaw-Saliba, Robin L Dewar, Marc Teitelbaum, Ven Natarajan, Sylvain Laverdure, Helene C Highbarger, M Tauseef Rehman, Susan Vogel, David Vallée, Page Crew, Negin Atri, Adam J Schechner, Sarah Pett, Fleur Hudson, Jonathan Badrock, Giota Touloumi, Samuel M Brown, Wesley H Self, Crystal M North, Adit A Ginde, Christina C Chang, Anthony Kelleher, Stephanie Nagy-Agren, Shikha Vasudeva, David Looney, Hien H Nguyen, Adriana Sánchez, Amy C Weintrob, Birgit Grund, Shweta Sharma, Cavan S Reilly, Roger Paredes, Agnieszka Bednarska, Norman P Gerry, Abdel G Babiker, Victoria J Davey, Annetine C Gelijns, Elizabeth S Higgs, Virginia Kan, Gail Matthews, B Taylor Thompson, Philippe Legenne, Richa Chandra, H Clifford Lane, James D Neaton, Jens D Lundgren, David Sahner, John Tierney, Betsey R Herpin, Mary C Smolskis, Laura A Mckay, Kelly Cahill, Ratna Sardana, Sharon Segal Raim, Lisa Hensely, Joshua Lorenzo, Rebecca Mock, Judith Zuckerman, Mark Miller, Lucy Chung, Nayon Kang, Stacey J Adam, Sarah Read, Ruxandra Draghia-Akli, Amy Carlsen, Anita Carter, Eileen Denning, Alain Duchene, Kate Eckroth, Alex Frase, Greg Gandits, Merrie Harrison, Payton Kaiser, Joseph Koopmeiners, Sue Meger, Thomas Murray, Kien Quan, Siu Fun Quan, Greg Thompson, Jamie Walski, Deborah Wentworth, Alan J Moskowitz, Emilia Bagiella, Ellen Moquete, Karen O’sullivan, Mary E Marks

Annals of Internal Medicine, doi:10.7326/m22-1503

Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. Objective: To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone.

Author contributions are available at Annals.org.

References

Accardi, Shaw-Saliba, Phd; Robin, Dewar, None, PhD

Adit, Ginde, Md, Mph, None

Almasri, Md, None

Atri, Barkauskas, Brown, Chandra, Chang et al., Ensovibep for Adults Hospitalized With COVID-19 ORIGINAL RESEARCH Annals.org Author Contributions: Conception and design

Atri, Mph, None

Babiker, Phd, Victoria, Davey, Phd et al., None

Badrock, Bsc, None

Baduashvili, Md, None

Barmparessou, Md, None

Bednarska, Md, None

Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -final report, N Engl J Med, doi:10.1056/NEJMoa2007764

Binz, Amstutz, Kohl, High-affinity binders selected from designed ankyrin repeat protein libraries, Nat Biotechnol

Braun, Md; Huldrych, Günthard, Ramachandruni, None

Chang, Md, None

Chen, Md, None

Chen, Nirula, Heller, BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2029849

Cohen, Nirula, Mulligan, 2 Investigators. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.8828

Davey Rt, Fernández-Cruz, Markowitz, Study Group. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial, Lancet Respir Med, doi:10.1016/S1473-3099(20)30483-7

Dougan, Nirula, Azizad, BLAZE-1 Investigators. Bamlanivimab plus etesevimab in mild or moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2102685

Gerry, None

Grandits, Ms; Nilima, Mosaly, Md, None

Grund, Neaton, Phillips, Reilly, Shehadeh et al., Collection and assembly of data

Grund, None

Gupta, Gonzalez-Rojas, Juarez, Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med, doi:10.1056/NEJMoa2107934

Hatlen, Md, None

Hien, Nguyen, Md, None

Highbarger, Tauseef Rehman, None

Hudson, Ba, None

Hughes, Md; Sanjay, Bhagani, Md, None

Hui, Bbio, Leither, Do, None

Kaczynski, Bsc, Evangelia, Mylona, None, MSc

Kan, Md, None

Kelleher, Mbbs, Phd, Bsc, Nagy-Agren et al., None

Kidega, Mbchb, Mmed, None

Kim, Md, None

Kimuli, Mbchb, Mmed, None

Kirk, Knowlton, Md; Mamta, Jain, Md et al., None

Konstantinos, Syrigos, Md, None

Kumarasamy, Abrishamian, Bonten, Interim results from the randomised, controlled EMPATHY phase 2/3 study evaluating ensovibep, a DARPin therapeutic, in patients with mildto-moderate COVID-19

Legenne, Md, Chandra, Mbbs, Lane et al., None

Looney, Md, None

Lundgren, Drs, Barkauskas, Mylonakis, and Young contributed equally to this work

Lundgren, Grund, Barkauskas, ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2033130

Lundgren, Grund, Barkauskas, Study Group. Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels. A randomized controlled trial, Ann Intern Med, doi:10.7326/M21-3507

Lutaakome, Mbchb, Mph, None

Lye, Mbbs, None

Marines-Price, Phd, Osuji, Rn, Bsn et al., None

Matthay, Md, None

Matthews, Mbchb, Phd, Taylor Thompson, None

Menon, Md, None

Montgomery, Hobbs, Padilla, Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Respir Med, doi:10.1016/S2213-2600(22)00180-1

Murray, Babiker, Baker, Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3), Clin Trials, doi:10.1177/17407745211049829

Mylonakis, Md, Poulakou, Md, None

O'brien, Forleo-Neto, Sarkar, COVID-19 Phase 3 Prevention Trial Team. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.24939

Overcash, Kalomenidis, Md, None

Paredes, Md, None

Pett, Md, None

Phillips, Phd, Daniel, Murray, Phd et al., None

Protopapas, Md, Koulouris, Md, None

Rapti, Md, None

Rapti, Robinson, Sandkovsky, Shehadeh, Siegel et al., Critical revision for important intellectual content

Robinson, Md, None

Rodger, Md, None

Rogers, Shehadeh, None, MSc

Rothenberger, Hurdiss, Walser, Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants. bioRxiv, doi:10.1101/2021.02.03.429164

Sandkovsky, Md, Ms; Robert, Gottlieb, Nnakelu et al., None

Schechner, Md, None

Sebudde, Mbchb, None

Sharma, Ms; Cavan, Reilly, None

Stumpp, Dawson, Binz, Beyond antibodies: the DARPin drug platform, BioDrugs, doi:10.1007/s40259-020-00429-8

Sánchez, Ms; Amy, Weintrob, Md, None

Takashita, Kinoshita, Yamayoshi, Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant

Teitelbaum, Md, Ms, None

Torbati, Kiweewa, Mbchb, Mmed, Mph, None

Touloumi, Phd, Samuel, Brown, Md; Wesley et al., None

Trautner, Md, None

Vall Ee, Pharmd, Crew, Pharmd, Mph, None

Vasudeva, Md, None

Vekstein, Md, None

Ven Natarajan, Phd; Sylvain Laverdure, None

Vogel, Rn, Bsn, None

Walser, Rothenberger, Hurdiss, Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates. bioRxiv, doi:10.1101/2020.08.25.256339

Waters, Md, None

Weinreich, Sivapalasingam, Norton, Trial Investigators. REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2108163

Weinreich, Sivapalasingam, Norton, Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2035002

Young, Md, Phd, David, Vock et al., None

Zepeda, Md, None

{ 'indexed': {'date-parts': [[2022, 8, 8]], 'date-time': '2022-08-08T21:41:39Z', 'timestamp': 1659994899477}, 'reference-count': 22, 'publisher': 'American College of Physicians', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.7326/m22-1503', 'type': 'journal-article', 'created': {'date-parts': [[2022, 8, 8]], 'date-time': '2022-08-08T21:00:22Z', 'timestamp': 1659992422000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19', 'prefix': '10.7326', 'author': [{'name': 'ACTIV-3/TICO Study Group*', 'sequence': 'first', 'affiliation': []}], 'member': '4285', 'published-online': {'date-parts': [[2022, 8, 9]]}, 'reference': [ {'key': 'r1-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2107934'}, {'key': 'r2-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.8828'}, {'key': 'r3-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2108163'}, {'key': 'r4-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2035002'}, {'key': 'r5-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2029849'}, { 'key': 'r6-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(21)00751-9'}, {'key': 'r7-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2033130'}, { 'key': 'r8-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(22)00215-6'}, {'key': 'r9-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2119407'}, { 'key': 'r10-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(22)00163-5'}, {'key': 'r11-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40259-020-00429-8'}, {'key': 'r12-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nbt962'}, { 'key': 'r13-M221503', 'doi-asserted-by': 'crossref', 'unstructured': 'Rothenberger S, Hurdiss DL, Walser M, et al. Ensovibep, a novel ' 'trispecific DARPin candidate that protects against SARS-CoV-2 variants. ' 'bioRxiv. Preprint posted online 26 February 2022. \xa0' 'doi:10.1101/2021.02.03.429164', 'DOI': '10.1101/2021.02.03.429164'}, { 'key': 'r14-M221503', 'doi-asserted-by': 'crossref', 'unstructured': 'Walser M, Rothenberger S, Hurdiss DL, et al. Highly potent ' 'anti-SARS-CoV-2 multivalent DARPin therapeutic candidates. bioRxiv. ' 'Preprint posted online 21 July 2021. \xa0doi:10.1101/2020.08.25.256339', 'DOI': '10.1101/2020.08.25.256339'}, {'key': 'r16-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/17407745211049829'}, { 'key': 'r17-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(19)30253-X'}, { 'key': 'r18-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30483-7'}, {'key': 'r19-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, {'key': 'r20-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2102685'}, {'key': 'r21-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.24939'}, { 'key': 'r22-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(22)00180-1'}, {'key': 'r23-M221503', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M21-3507'}], 'container-title': 'Annals of Internal Medicine', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2022, 8, 8]], 'date-time': '2022-08-08T21:00:25Z', 'timestamp': 1659992425000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.acpjournals.org/doi/10.7326/M22-1503'}}, 'subtitle': ['A Randomized Controlled Trial'], 'short-title': [], 'issued': {'date-parts': [[2022, 8, 9]]}, 'references-count': 22, 'alternative-id': ['10.7326/M22-1503'], 'URL': 'http://dx.doi.org/10.7326/M22-1503', 'relation': {}, 'ISSN': ['0003-4819', '1539-3704'], 'subject': ['General Medicine', 'Internal Medicine'], 'container-title-short': 'Ann Intern Med', 'published': {'date-parts': [[2022, 8, 9]]}}

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0